Abstract:Background: Chemotherapy is one of the most common therapies used in the treatment of colorectal cancer (CRC), but chemoresistance inevitably occurs. It is challenging to obtain an immediate and accurate diagnosis of chemoresistance. The potential of circulating exosomal miRNAs as oxaliplatin-based chemoresistant biomarkers in CRC patients was investigated in this study.Methods: Plasma exosomal miRNAs in sensitive and resistant patients were analyzed by miRNA microarray analysis, followed by verification with a quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assay in two independent cohorts. The diagnostic accuracy was determined by ROC curve analysis. Logistic regression analysis and Spearman's rank correlation test were also performed. Finally, bioinformatics was used to preliminarily explore the potential molecular mechanism of the selected miRNAs in chemoresistance.Results: miRNA microarray analysis identified four upregulated miRNAs and 20 downregulated miRNAs in chemoresistant patients compared to chemosensitive patients. Twelve markedly dysregulated miRNAs were selected for further investigation, of which six (miR-100, miR-92a, miR-16, miR-30e, miR-144-5p, and let-7i) were verified to be significantly and consistently dysregulated (>1.5-fold, P < 0.05). The combination of the six miRNAs had the highest AUC (0.825, 95% CI, 0.753–0.897). The expression level of these 6 miRNAs was not correlated with tumor location, stage, or chemotherapy program. Only miR-100 was significantly upregulated in low histological grade. GO analysis and KEGG pathway analysis showed that miRNAs were related to RNA polymerase II transcription and enriched in the PI3K-AKT signaling pathway, AMPK signaling pathway, and FoxO signaling pathway.Conclusions: We identified a panel of plasma exosomal miRNAs, containing miR-100, miR-92a, miR-16, miR-30e, miR-144-5p, and let-7i, that could significantly distinguish chemoresistant patients from chemosensitive patients. The detection of circulating exosomal miRNAs may serve as an effective way to monitor CRC patient responses to chemotherapy. Targeting these miRNAs may also be a promising strategy for CRC treatment.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to effectively identify biomarkers for resistance to oxaliplatin - based chemotherapy in patients with colorectal adenocarcinoma (CRC). Specifically, the study aims to explore whether the plasma exosome miRNA expression profile can be used as a biomarker for detecting oxaliplatin - chemotherapy resistance in CRC patients. The solution to this problem is of great significance for timely adjustment of treatment regimens and improvement of treatment effects. ### Research Background Chemotherapy is one of the most commonly used methods for treating colorectal cancer (CRC), but chemotherapy resistance is a common challenge. Currently, there is a lack of a rapid and accurate method in clinical practice to diagnose chemotherapy resistance. Therefore, it is very necessary to find effective biomarkers to identify resistant patients early. ### Research Methods 1. **Sample Collection**: Plasma samples were collected from 210 patients with advanced CRC (stage III - IV). These samples were collected either before chemotherapy or immediately after being diagnosed as having progressive disease (PD) or partial response (PR). 2. **Exosome Isolation and RNA Extraction**: Total Exosome Isolation Kit was used to isolate exosomes from plasma, and miRNeasy Kit was used to extract RNA. 3. **miRNA Microarray Analysis**: miRNA microarray analysis was used to screen for miRNAs with differential expression between the resistant and sensitive groups. 4. **RT - qPCR Verification**: RT - qPCR was used to verify the expression levels of candidate miRNAs in an independent cohort. 5. **Statistical Analysis**: The diagnostic value of candidate miRNAs was evaluated by ROC curve analysis, the risk score was evaluated by binary logistic regression analysis, and the correlation between miRNAs and clinical parameters was evaluated by Spearman rank - correlation test. 6. **Bioinformatics Analysis**: GO and KEGG pathway analyses were performed to predict the target genes of candidate miRNAs and their biological functions. ### Main Results 1. **miRNA Screening**: Through miRNA microarray analysis, 4 up - regulated and 20 down - regulated miRNAs were screened out. 2. **Verification Results**: Twelve miRNAs with significant differential expression were verified in an independent cohort, and finally 6 miRNAs (miR - 100, miR - 92a, miR - 16, miR - 30e, miR - 144 - 5p, and let - 7i) were determined to have significant differences in expression between the resistant and sensitive groups. 3. **Diagnostic Accuracy**: The AUC value of the combination of these 6 miRNAs was 0.825, which was significantly higher than the diagnostic value of a single miRNA. 4. **Bioinformatics Analysis**: GO and KEGG pathway analyses showed that these miRNAs may be involved in chemotherapy resistance by regulating RNA polymerase II transcription, PI3K - Akt signaling pathway, AMPK signaling pathway, and FoxO signaling pathway. ### Conclusion The study found that the plasma exosome miRNA expression profile can be used as an effective biomarker to distinguish CRC patients who are resistant to oxaliplatin chemotherapy. The detection of these miRNAs not only helps to monitor the chemotherapy response of patients but may also provide new strategies for the treatment of CRC.

Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma

Hsa-miR-483-5p/mRNA network that regulates chemotherapy resistance in locally advanced rectal cancer identified through plasma exosome transcriptomics

Exosomes Containing Differential Expression of Microrna and Mrna in Osteosarcoma That Can Predict Response to Chemotherapy.

Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer

Diagnostic Potential Of Serum Exosomal Colorectal Neoplasia Differentially Expressed Long Non-Coding Rna (Crnde-P) And Microrna-217 Expression In Colorectal Carcinoma

Plasma proteome profiling reveals biomarkers of chemotherapy resistance in patients with advanced colorectal cancer

MicroRNA Profiling Of Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells

Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer

Exosome secretion related gene signature predicts chemoresistance in patients with colorectal cancer

miR-5000-3p confers oxaliplatin resistance by targeting ubiquitin-specific peptidase 49 in colorectal cancer

Exosome-Encapsulated Micrornas As Circulating Biomarkers For Colorectal Cancer

The microRNA of advanced colorectal cancer predict efficacy of first-line chemotherapy

Identification of key lncRNAs associated with oxaliplatin resistance in colorectal cancer cells and isolated exosomes: From In-Silico prediction to In-Vitro validation

Plasma Micrornas Are Promising Novel Biomarkers for Early Detection of Colorectal Cancer

Plasma miR-122-5p and miR-142-5p and their role in chemoresistance of colon cancer patients

Identification of stage-associated exosome miRNAs in colorectal cancer by improved robust and corroborative approach embedded miRNA-target network

Plasma Mir-601 And Mir-760 Are Novel Biomarkers For The Early Detection Of Colorectal Cancer

Plasma Microrna Signatures to Predict Egfr-Tki Resistance in Egfr-Mutant Advanced Nsclc Patients.

The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer